Literature DB >> 31139586

An Unusual Presentation of Metastatic Breast Carcinoma.

Maria Mendonça-Sanches1, Inês Rolim2, José Cabeçadas2, Margarida Rafael3.   

Abstract

Cutaneous metastasis from a carcinoma is a relatively uncommon phenomenon. Prompt diagnosis is crucial, as it will have future implications, particularly regarding prognosis and treatment. Skin metastases can be suspected and recognized earlier through physical examination than metastases in other organs or systems. However, they can be a diagnostic challenge due to the variable clinical presentation. This case highlights the importance of having a high index of suspicion for cutaneous metastases, especially in patients with a previous history of cancer. LEARNING POINTS: Cutaneous metastases occur in approximately 0.7-10% of patients with invasive carcinomas and, when present, usually indicate an unfavourable outcome.Clinically, cutaneous metastasis can pose a diagnostic challenge and a high index of suspicion is mandatory for a prompt diagnosis.Skin biopsy of such lesions is important to confirm the diagnosis and, in the right clinical scenario, they can provide information on the primary origin of the tumour.

Entities:  

Keywords:  Cutaneous metastases; breast carcinoma; invasive carcinomas; skin biopsy

Year:  2019        PMID: 31139586      PMCID: PMC6499091          DOI: 10.12890/2019_001089

Source DB:  PubMed          Journal:  Eur J Case Rep Intern Med        ISSN: 2284-2594


INTRODUCTION

Cutaneous metastases are defined as neoplastic lesions affecting the dermis or the subcutaneous tissue that originate from another primary malignancy. They are a relatively uncommon phenomenon with a reported incidence in the literature ranging from 0.7% to 10% [. Once diagnosed, cutaneous metastases indicate a poor clinical outcome as they are related to a higher stage, later course and/or an unsuccessful response to treatment[. Compared with metastases in other organs or systems, skin metastases can be suspected and promptly recognized by a clinician through physical examination[. However, the clinical presentation can be a diagnostic challenge as the lesions are frequently asymptomatic and may present in variable forms such as papules, nodules, plaques, or inflammatory and bullous lesions[. Skin biopsy evaluation of such lesions is fundamental as it can provide information on the primary origin of the tumour[.

CASE REPORT

A 52-year-old Caucasian woman was seen in our outpatient clinic for the recent appearance over the previous 6 months of numerous asymptomatic skin lesions on the neck, trunk and proximal regions of the upper and lower limbs. Her medical history included a diagnosis of right-sided invasive lobular breast carcinoma (cT3N+, oestrogen and progesterone receptor positive, ERBB2 negative) 9 years earlier. She had undergone neoadjuvant chemotherapy and a right radical mastectomy followed by local radiotherapy, adjuvant chemotherapy and 5 years of endocrine therapy with tamoxifen. In the past 2 years, stage IV breast cancer with multifocal metastatic bone disease had been documented. Letrozole therapy was given initially, with partial response, but during the previous year there had been continuing on-going symptomatic bone involvement. The patient had declined further medical treatment and initiated alternative therapies, namely ozonotherapy. On physical examination, multiple skin-coloured to brown papules were seen on the neck, trunk, arms and thighs (Fig. 1). A punch biopsy was performed and confirmed the diagnosis of cutaneous infiltration by neoplastic cells, compatible with metastatic lobular carcinoma of the breast (Fig. 2).
Figure 1

Multiple skin-coloured to brown papules on (A) the upper chest and (B) the upper back

Figure 2

(A) Epithelial cells infiltrate the superficial and reticular dermis. (B) The tumour cells show moderate nuclear atypia and scant eosinophilic cytoplasm. (C) Positive nuclear staining for oestrogen receptors in the neoplastic cells

DISCUSSION

Cutaneous metastases occur in approximately 0.7–10% of patients with invasive carcinomas. Although uncommon, and comprising approximately 2% of all skin tumours, when present they usually predict a poor prognosis[. These skin manifestations are usually seen in patients with advanced disease, but they can be the presenting sign of a neoplastic disorder in 12% of the patients[. According to the literature, skin metastasis can be the first sign of metastatic involvement, particularly in breast cancer (in 23.9% of patients) and melanoma[. El Khoury et al. reported that in these patients, the most common primary origin was breast carcinoma in women and laryngeal carcinoma in men[. With an aging population and increases in the average life expectancy and the incidence of cancer, the global burden of cancer is expected to grow. It is therefore important for clinicians and pathologists to be aware of the clinical spectrum of cutaneous metastases, and to have a high index of suspicion for early diagnosis and prompt management[. Gan et al. reported that in a cohort of 35 patients with confirmed cutaneous metastases, the diagnosis was suspected in 72% (n=25), based on clinical features (46%, n=16) or the presence of active metastatic disease elsewhere (26%, n=9)[. Accurate recognition of cutaneous metastases on biopsy examination is also crucial. In cases of an unknown primary tumour, histological and immunohistochemical evaluation is important to guide clinical and imaging investigations. Moreover, in cases of a previously documented tumour, cutaneous metastases may upstage the tumour and change the prognosis[. In summary, the presented clinical case highlights the importance of early assessment of patients with cutaneous lesions, especially if there is a previous history of cancer, regardless of stage of treatment. This may lead to the prompt diagnosis of cutaneous metastases, which will have future implications, particularly regarding clinical outcome and treatment options.
  9 in total

1.  Cutaneous metastases of internal malignancies: a clinicopathologic study.

Authors:  Rajan Chopra; Seema Chhabra; Spinderjeet Gill Samra; Gurvinder Pal Thami; Raj Pal Singh Punia; Harsh Mohan
Journal:  Indian J Dermatol Venereol Leprol       Date:  2010 Mar-Apr       Impact factor: 2.545

2.  Cutaneous metastases in patients with metastatic carcinoma: a retrospective study of 4020 patients.

Authors:  D P Lookingbill; N Spangler; K F Helm
Journal:  J Am Acad Dermatol       Date:  1993-08       Impact factor: 11.527

3.  A retrospective review of cutaneous metastases at the National Skin Centre Singapore.

Authors:  Emily Yiping Gan; Martin Tze-Wei Chio; Wee Ping Tan
Journal:  Australas J Dermatol       Date:  2014-09-01       Impact factor: 2.875

4.  Cutaneous metastasis: a clinical, pathological, and immunohistochemical appraisal.

Authors:  Sadia Saeed; Connie A Keehn; Michael B Morgan
Journal:  J Cutan Pathol       Date:  2004-07       Impact factor: 1.587

5.  Cutaneous metastasis: clinicopathological study of 72 patients from a tertiary care center in Lebanon.

Authors:  Jinane El Khoury; Ibrahim Khalifeh; Abdul-Ghani Kibbi; Ossama Abbas
Journal:  Int J Dermatol       Date:  2013-04-04       Impact factor: 2.736

6.  Clinicopathologic correlation of cutaneous metastases: experience from a cancer center.

Authors:  Dinesh Sariya; Karen Ruth; Rose Adams-McDonnell; Carrie Cusack; XiaoWei Xu; Rosalie Elenitsas; John Seykora; Terri Pasha; Paul Zhang; Marisa Baldassano; Stuart R Lessin; Hong Wu
Journal:  Arch Dermatol       Date:  2007-05

7.  Cutaneous metastases from different internal malignancies: a clinical and prognostic appraisal.

Authors:  S C-S Hu; G-S Chen; Y-W Lu; C-S Wu; C-C E Lan
Journal:  J Eur Acad Dermatol Venereol       Date:  2008-02-26       Impact factor: 6.166

8.  Cutaneous metastasis: a meta-analysis of data.

Authors:  Richard A Krathen; Ida F Orengo; Ted Rosen
Journal:  South Med J       Date:  2003-02       Impact factor: 0.954

Review 9.  Cutaneous metastatic disease.

Authors:  R A Schwartz
Journal:  J Am Acad Dermatol       Date:  1995-08       Impact factor: 11.527

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.